Sugi Predict

Sugi Predict / Targets / CCNB3

CCNB3

G2/mitotic-specific cyclin-B3 · Q8WWL7 · CCNB3 on Sugi Atlas →

64,038 patent compounds predicted against CCNB3, 41,421 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL490814 SCHEMBL490814 1.00 20/20
SCHEMBL490541 SCHEMBL490541 0.72 20/20
SCHEMBL490777 SCHEMBL490777 0.72 20/20
Kenpaullone Kenpaullone (SCHEMBL79889) 1.00 19/20
SCHEMBL490933 SCHEMBL490933 1.00 19/20
SCHEMBL491100 SCHEMBL491100 1.00 19/20
SCHEMBL489971 SCHEMBL489971 1.00 18/20
SCHEMBL490489 SCHEMBL490489 1.00 18/20
SCHEMBL490667 SCHEMBL490667 1.00 18/20
SCHEMBL490671 SCHEMBL490671 1.00 18/20
SCHEMBL490775 SCHEMBL490775 1.00 18/20
SCHEMBL490811 SCHEMBL490811 1.00 18/20
SCHEMBL491124 SCHEMBL491124 1.00 18/20
Bromide Bromide (SCHEMBL490969) 0.97 18/20
SCHEMBL490088 SCHEMBL490088 0.63 18/20
SCHEMBL491139 SCHEMBL491139 0.59 18/20
Aloisine Aloisine (SCHEMBL79714) 1.00 17/20
Aloisine A Aloisine A (SCHEMBL80147) 1.00 17/20
SCHEMBL490379 SCHEMBL490379 1.00 17/20
SCHEMBL490878 SCHEMBL490878 1.00 17/20

Clinical trials — most relevant to CCNB3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer PHASE2/PHASE3NOT_YET_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. PHASE1/PHASE2COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma PHASE2COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
A Study of BN104 in the Treatment of Acute Leukemia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas PHASE1COMPLETED
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets PHASE1UNKNOWN
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) PHASE1COMPLETED
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Tamoxifen in Patients With Oesophageal Cancer PHASE1UNKNOWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer nanCOMPLETED
Strigolactones and Dysplastic Colonic Lesions or Cancer nanUNKNOWN
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence nanUNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CCNB3 binder may also engage these)

ProteinNameSimilarity
Q659K0 — 1.000 Q659K0 →
Q8TCU4 — 0.986 Q8TCU4 →
Q9BXL5 — 0.986 Q9BXL5 →
Q9BXX2 — 0.984 Q9BXX2 →
Q810T2 — 0.983 Q810T2 →
Q32L62 — 0.982 Q32L62 →
A6NJ88 — 0.981 A6NJ88 →
Q3V3Q4 — 0.980 Q3V3Q4 →
Q8N3K9 — 0.980 Q8N3K9 →
Q6P902 — 0.979 Q6P902 →
Q920R4 — 0.979 Q920R4 →
Q5JRC9 — 0.979 Q5JRC9 →
Q95JY5 — 0.979 Q95JY5 →
Q9HCK1 — 0.979 Q9HCK1 →
Q5XHX6 — 0.978 Q5XHX6 →
A2T7F2 — 0.978 A2T7F2 →
A1YGK6 — 0.978 A1YGK6 →
Q5U4C1 — 0.978 Q5U4C1 →
Q9P1V8 — 0.977 Q9P1V8 →
Q68DN1 — 0.977 Q68DN1 →
Q5H9T9 — 0.977 Q5H9T9 →
Q95J40 — 0.977 Q95J40 →
Q96M34 — 0.976 Q96M34 →
A1EGX6 — 0.976 A1EGX6 →
Q8N2N9 — 0.976 Q8N2N9 →
Q8K4E0 — 0.976 Q8K4E0 →
Q70KF4 — 0.975 Q70KF4 →
Q96JA4 — 0.975 Q96JA4 →
A4FU49 — 0.975 A4FU49 →
Q6ZRG5 — 0.974 Q6ZRG5 →